Evaluate Qiagen's (QGEN) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Qiagen NYSE: QGEN reported second-quarter 2026 results above its prior outlook, with net sales of $535 million, unchanged year over year on both a reported and constant-exchange-rate basis. The company had forecast an approximately 2% decline at constant exchange rates.
Qiagen N.V. (QGEN) Q2 2026 Earnings Call Transcript
| Professional Services Industry | Industrials Sector | Thierry L. Bernard CEO | CBOE Exchange | NL0015002SN0 ISIN |
| NL Country | 5,500 Employees | 7 Jul 2026 Last Dividend | 8 Jan 2026 Last Split | 28 Jun 1996 IPO Date |
Founded in 1984 and headquartered in Venlo, the Netherlands, QIAGEN N.V. is a global leader in providing comprehensive solutions that convert biological materials into valuable molecular insights. The company’s innovative portfolio spans a wide range of sectors including molecular diagnostics, academia, pharmaceutical, and applied testing. QIAGEN is dedicated to facilitating the process of acquiring insights from biological samples through its extensive array of technologies and products, designed to support various stages of molecular analysis.